Medtronic and Covidien could close their $43 billion mega-merger by the end of the month, according to a regulatory filing.
Medtronic's shareholders overwhelmingly approved its proposed, $43 billion merger with Covidien this week, including a controversial provision to cover a portion of its executives tax bills.
Covidien's Stellarex drug-eluting balloon, which it's slated to deal to Spectranetics after the closure of its buyout by Medtronic, wins CE Mark approval in the European Union.
European regulators granted market clearance for Covidien's (NYSE:COV) Stellarex drug-eluting balloon for treating peripheral artery disease, the company said today.
Four medtech companies make CB Insights list of the top 20 venture capital-backed healthcare exits of 2014.
At least 4 medtech exits were significant enough to make the cut for the top 20 venture capital-backed healthcare exits of 2014, according to research firm CB Insights.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Stryker buys Canadian hospital bed maker CHG; Tornier extends U.S. anti-trust waiting period on merger with Wright Medical; Covidien shareholders approve Medtronic merger; Becton Dickinson, CareFusion settle lawsuits filed over merger; Medtronic shareholders also OK Covidien deal
Covidien's Nellcor ventillators have been burdened with another Class I recall due to a manufacturing mishap.
Medtronic's shareholders overwhelmingly approve its $43 billion merger with Covidien, setting the stage for the deal to close in a few weeks.